AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2639-4162/062
1 Laboratory Service, National Hospital Center of Nouakchott, Mauritania.
2 Faculty of Medicine of Nouakchott, Mauritania.
*Corresponding Author: Mohamed Lemine Ould SALEM, Laboratory Service, National Hospital Center of Nouakchott, Mauritania.
Citation: Mohamed Lemine Ould SALEM, Ahmedna Sidi Abdalla, Ghaber Sidi Mohamed (2022). Hepatitis B and Delta Co-Infection: Prevalence and Serological Characteristics in Mauritania. J. General Medicine and Clinical Practice. 5(1); DOI:10.31579/2639-4162/062
Copyright: © 2022 Mohamed Lemine Ould SALEM, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 17 May 2022 | Accepted: 26 May 2022 | Published: 31 May 2022
Keywords: HBV; HDV; co-infection; nouakchott; mauritania
Background: Hepatitis B is one of the major public health concerns worldwide. In Mauritania, its prevalence in the general population is very high. The hepatitis D virus (HDV) borrows the envelope from the hepatitis B virus (HBV) during its infectious cycle. We thus observe co-infections during which the two viruses are acquired simultaneously and superinfections by HDV in patients who are already chronic carriers of the B virus.
Objective: to assess the prevalence of HBV and HDV infection
Material and Methods: this is a prospective descriptive study, conducted from January 1 to November 30, 2017 in the two medical analysis laboratories in Nouakchott. Patients were included: all patients of both sexes and of all ages carrying HBsAg presenting to the two medical analysis laboratories during this period.
Results: in 12 month, 211 patients with HBsAg were notified out of a total of 1675 patients screened, i.e. a prevalence of 12.59%. HBV/HDV co-infection is 31.30%. The average age was 36 years with extremes [8 and 66]. The male/female sex ratio was 1.45. The mean HBV viral load was 2.68 ± 1.31 log IU/ml [range: 478.63 IU/ml ± 20.41]. The majority (94.9%) of patients were HBeAg negative.
Conclusion: HBV/HDV co-infection remains very high in our country. This study indicates that the significant morbidity of the two viruses associated with limited knowledge of the mode of transmission, constitute factors of vulnerability.
Hepatitis B virus (HBV) infection remains a national and global public health problem. A ubiquitous disease, according to the World Health Organization (WHO), two billion people worldwide are infected with the hepatitis B virus (HBV), of which 370 to 400 million are chronic carriers of the HBs antigen [1]. Of these, 15 to 25% will die prematurely from a hepatic complication, mainly cirrhosis or hepatocellular carcinoma [1-3]. In Africa the infection is endemic, an estimated 65 million chronic carriers of HBV [2].
In Mauritania, few epidemiological studies are available but it is estimated that the overall prevalence of HBsAg is greater than 10.7% [5-7]. Under the natural conditions of infection, HDV only spreads in the presence of the hepatitis B virus from which it borrows the envelope. We thus observe co-infections during which the two viruses are acquired simultaneously and superinfections by HDV in patients who are already chronic carriers of the B virus [8]. About a quarter of chronic carriers of HBsAg are co-infected with the hepatitis D virus [2, 9-12]. In developing countries, most HBV and HDV infections occur during the perinatal period (vertical transmission) in more than 90% of cases [13,14]. To our knowledge, data on the prevalence of HBV/HDV coinfection in Mauritania are rare. Therefore, it is relevant to know the prevalence of HDV in chronic carriers of HBsAg in two medical analysis laboratories in Nouakchott. This would allow us to know the impact of HBV/HDV coinfection in our context and to propose a preventive and curative strategy.
Patients and Methods:
This is a prospective, single-center observational study on the prevalence of VHD in chronic HBsAg carriers at the two medical analysis laboratories (Maurilab medical analysis laboratory and Medilab medical analysis laboratory) during the study period from January 1 to November 30, 2017.
Included in this study were all patients carrying HBsAg screened in the two medical analysis laboratories during the study period. Data collection was carried out using a previously tested questionnaire. They focused on socio-demographic attributes and medical data (age, sex, origin, reason for hospitalization, previous treatment, physical and biological signs, evolution and complications). The search for anti-HDV AC was carried out in all HBsAg positive patients. An additional assessment (hepatitis B viral load, HBeAg, anti-HBe AC, anti-HBc AC, ALT, AFP) was performed in our patients.
Data analysis was performed using SPSS Statistic 20 software.
Limitation of the study:
Absence of HDV viral load data and imaging data
During the 12-month period, 211 cases were collected, or an average of 17 cases per month. These 211 cases represented 14.96% of all screened during the same period (1410 screened)
The average age of the patients was 36.3 ± 12.5 years with extremes of 8 and 66 years and years and the most affected age groups were as follows: 40-49 years (27.9% of cases), 20-29 years (24.41% of cases). The distribution of patients according to age groups is shown in Table 1
The M/F sex-ratio was 1.45 but the majority of the infection concerned men (125/211 or 59.2%).
The search for AC-anti-hepatitis Delta virus (AC HDV) was performed in all of our patients and was positive in 66 cases (31.30%) (Table 2).
Quantitative measurement of viral DNA allowed us to individualize three groups of patients, 82.5% of them have a low viral load below 2000 IU/ml, 7.1% of patients have HBV DNA high above 20,000 IU/ml and 10.4% have an intermediate viral load between 2000 and 20,000 IU/ml.
The distribution of patients according to HBV viral load is shown in Figure 1.
3.6. Distribution of co-infected patients according to HBV viral load:
Among the 66 AC HDV positive patients, 53 patients (80.3% of patients) had a viral load below 2000 IU/ml, 6 patients (9.1%) had an intermediate viral load between 2000 and 20,000 IU/ml. ml and 7 patients (10.6%) have a high viral load above 20,000 IU/ml. Figure 2 shows the distribution of co-infected patients according to HBV viral load.
3.7. Distribution of patients according to ALT level and HBV viral load:
- 63% of patients had a normal ALT level and a viral load below 2000IU/ml;
-5% of patients had a normal ALT level and an intermediate load of between 2000 and 20,000IU/ml;
-3% of patients had a normal ALT level and a viral load above 20,000IU/ml;
-10% of patients had an ALT level one to two times normal and a viral load below 2000IU/ml;
-4% of patients had an ALT level one to twice normal and an intermediate viral load between 2000 and 20,000IU/ml;
-2% of patients had an ALT level one to two times normal and a viral load greater than 20,000IU/ml;
-6% of patients had an ALT level more than twice normal and a viral load below 2000IU/ml;
-1% of patients had an ALT level more than twice normal and an intermediate viral load between 2000 and 20,000IU/ml;
-6% of patients had an ALT level more than twice normal and a viral load greater than 20,000UI/ml.
Figure 3 shows the distribution of patients according to ALT level and HBV viral load.
3.8. Distribution of co-infected patients according to ALT level:
- 63.04% of patients had a normal ALT level;
-19.56% of patients had an ALT level one to two times normal;
-17.4% of patients had an ALT level more than twice normal.
3.9. Distribution of patients according to HBe status:
Out of 97 patients among the 211 HBV carriers, 92 HBeAg (-) patients (i.e. 94.9% of patients) and 5 patients (i.e. 5.1%) HBeAg (+) were found (table 3).
3.10. Relationship of HBe seroconversion and HBV viral load:
Among the 92 HBeAg negative patients, 78 patients (i.e. 84.8%) have a viral load below 2000 IU/ml, 7 patients (i.e. 7.6%) have an intermediate viral load between 2000 and 20,000 IU/ml, and 7 patients (7.6%) have a high viral load above 20,000 IU/ml.
Among the 5 HBeAg positive patients, 2 patients had an intermediate viral load between 2000 and 20,000 IU/ml and 3 patients had a high viral load greater than 20,000 IU/ml (Table 4).
3.11. Relationship of HBe seroconversion and co-infection:
Among the 92 HBeAg negative patients, 29 have positive HDV AC and among the 5 HBeAg positive patients 3 have positive HDV AC.
3.12. Distribution of patients according to alpha-fetoprotein level and HBV viral load:
- 76.47% of patients had a normal AFP level and a viral load below 2000IU/ml;
-211.76% of patients had a normal AFP level and a viral load between 2000-20,000IU/ml;
-5.86% of patients had a high AFP level (380 ng/ml) and a viral load below 2000 IU/ml;
- 5.86% of patients had a high AFP level (28493ng/ml) and a viral load above 20,000IU/ml.
Chronic HBV/HDV co-infection is most often the cause of serious liver damage such as fulminant hepatitis, if compared to HBV mono-infection.
HBV/HDV superinfection is associated with chronic infection in 90% of virus carriers and rapidly progressing to cirrhosis and increased risk of hepatocellular carcinoma [11,12].
HBV and HDV co-infections are generally characterized by strong HDV replication with the coexistence of very weak HBV replication, which would be due to repression of B virus replication by Delta proteins [17].
In addition, concurrent infection with HDV complicates antiviral treatment, as HBV treatment regimens do not affect HDV replication [2]. The only treatment that has shown efficacy in chronic D infection is interferon-α. Stopping treatment at doses of 2.5 to 7.5 MU/m2 , 3 times a week for 2 to 16 weeks, is associated almost constantly with a relapse, which recommends that the dosage currently proposed is therefore 9 MU, 3 times a week for 48 weeks. At these dosages, side effects are numerous and can limit the feasibility of treatment [16].
4.1. Epidemiology:
4.1.1. Gender:
A significantly higher prevalence of HBsAg was observed in men. This could be a consequence of better shedding of infection by females, but there is currently no clear explanation for this higher rate of HBV infection in males although some behavioral aspects (e.g., the shaving, travel) may play a role [18].
In our study population of 211 patients with HBsAg, the breakdown by sex shows a male predominance with a frequency of 59.2% for men (n=125) and a frequency of 40.8% for women (n=86), i.e. a sex ratio of 1.45.
The male predominance is more evident in all studies carried out nationally and internationally.
In Mauritania, in a study of 300 patients chronically infected with HBV receiving care at the hepato-gastroenterology unit of the National Hospital of Nouakchott (CHN) between February and October 2009, reports a male predominance with a sex ratio 1.52 (184 M/116F) [19].
Among blood donors (DDS) carrying HBsAg in Mauritania, a male predominance with a sex ratio of 27 (431M/16F) [5].
In Morocco, a study carried out on 276 patients carrying HBsAg also showed a male predominance with a sex ratio M/F of 1.51 [20].
In Tunisia there is also a male predominance with a sex ratio of 1.02 [14].
The male predominance was also described in a study carried out in 2008 on 75 patients with HBV residing in northeastern Algeria with a sex ratio of 1.77 (48M/27F) [21].
In Cameroon, a study was carried out in the Gastroenterology Unit of the Yaoundé University Hospital Center, the Yaoundé General Hospital and the Cathedral Medical Center, from August 2012 to May 2013 on 128 patients chronically infected with HBV notes a male predominance of which 77 (60.16%) were men and 51 (39.84%) were women [22].
In Nigeria of 188 HBsAg positive serum specimens from outpatients recruited from four tertiary hospitals in southwestern Nigeria, 82 (43.6%) were female and 106 (56.4%) male [12].
Epidemiological data in France also show a predominant male representation of 51% [23].
4.1.2. Age:
The average age of our patients is 36 years old with extremes of 8 and 66 years old and the most represented age groups are 40-49 years old (27.90%) followed by 20-29 years old (24.41%) with no significant difference between the two sexes (p=0.5).
The young age of our patients could be explained by the fact that most patients are infected with hepatitis B at a young age (newborns: mother-child transmission which seems to play an important role in the maintenance of the virus in our country, grandchildren…); the complications that could constitute the reason for consultation generally appear late, and the screening of children is rarely carried out.
The young age of Mauritanian patients is also found in the Mauritanian studies cited above; Lunel-Fabiani F et al [19] found an average age of 36 years in patients chronically infected with HBV receiving care at the hepato-gastroenterology unit of the National Hospital of Nouakchott; Mansour W et al [7] also described an average age of 36 years among consulting patients, while Mansour W et al [5] found an average age of 31 years among blood donors; a lower age (26 years) has been described by Mansour W et al [7] in pregnant women.
Our results concerning age were compared with those of African countries: The average age of Algerian patients is similar to that of our patients, 35 years [21], 39 years in Moroccans [20], 28 years in Tunisians [14], 33 years among Cameroonians [22] and 32 years among Nigerians [12]. The average age of our patients is consistent with that found in France, 36 years [23].
In our series, the mean age in AC HDV positive patients is 37.2 ± 12.3 and in AC HDV negative patients is 35.4 ± 12.4 with a non-significant difference (p=0. 8), which is consistent with the results from Cameroon (p>0.05) [22] and the results from Tunisia, the mean age in AC HDV positive patients is 43 years and in AC HDV negative patients is aged 41 with a non-significant difference (p=0.12) [14].
However, these results are not consistent with the results obtained in blood donors in Mauritania, which shows that the average age was significantly higher in AC HDV positive donors compared to AC HDV negative donors (34.28 years ± 9.18 against 30.52 years ± 8.63, P = 0.001)[5] and are not consistent with the results of patients chronically infected with HBV followed at the National Hospital Center of Nouakchott (CHN) which shows that AC HDV positive patients were significantly older than AC HDV negative patients (41 ± 12 versus 33 ± 11 years, p < 0>
The mean age of HDV positive subjects was approximately five years older than that of the general HBsAg positive population in the different cohorts studied in Mauritania (p<0>
4.1.3. Prevalence of HBV/HDV co-infection:
In our series, the prevalence of HBV/HDV co-infection is 31.30%.
In Mauritania, according to a study carried out from July 2008 to July 2009 involving 1020 pregnant women and 946 consulting patients, CA HDV was found in 19% of HBs+ Ag consultants and in 14.7% of HBs+ Ag pregnant women [7].
In Mauritania, a study was conducted from October 2008 to December 2009 on 11,000 blood donors, 1,700 of whom were HBsAg positive, 90 donors were found to be AC HDV positive (ie 19.78% of patients) [5]. AC HDV was also sought in the 300 patients followed at the CHN and 98 (33.3%) were found to be AC HDV positive [19].
In Tunisia out of 1615 HBsAg positive patients, only 33 patients (i.e. 2%) had positive HDV AC [14].
In Algeria, the prevalence of HBV/HDV co-infection is 1.28% (1/78) [24].
In Senegal, the prevalence of CA HDV among asymptomatic HBsAg-positive subjects ranged from 4% in the north to 13% in Dakar and 44% in Pikine [25].
In Cameroon out of 128 patients chronically infected with HBV, 29 patients had positive HDV AC representing 22.66% [22].
In Nigeria, HDV AC was found in 12.5% of 96 HBsAg+ patients [26].
In 2009, an HDV CA rate of 66.7% was reported in Gabon [27].
Our results concerning the prevalence of HBV/HDV co-infection were compared with those of Western countries:
In France, among a total of 4492 DDS positive for HBsAg, 89 (1.98%) were AC HDV positive [10].
The seroprevalence of patients co-infected with HBV and HDV in Belgium is 5.5% (44/800) [28].
In Italy out of 488 subjects who tested positive for HBsAg, 24 were AC HDV positive (4.9%) [11].
The prevalence of HBV/HDV co-infection in the United States is 8% [29].
In Iran, the prevalence of HBV/HDV co-infection is 2.2% [9].
Overall, the prevalence of co-infection in our series is comparable to that of African countries but much higher than that described in developed countries (Europe and the United States).
Table 5 compares the prevalence of co-infection between our series and data from the literature
4.2. HBV viral load:
In our series, the quantification of the mean HBV viral load calculated is 2.68 ± 1.31 log IU/ml (i.e. 478.63 IU/ml ± 20.41). This quantitative measurement of viral DNA allowed us to individualize our patients into three groups; 82.5% of them have a low viral load of less than 2000 IU/ml; 7.1% have a high viral load greater than 20,000 IU/ml and 10.4% have an intermediate viral load between 2000 and 20,000 IU/ml. These results are comparable with the results found in DDS by Mansour W et al. [5] who showed that the average viral load was 2.0 ± 1.65 log IU/ml (i.e. 100 ± 44.7 IU/ml) and 7.9% of patients had an intermediate viral load between 2000 and 20,000 IU/ml/ and 9.8% were above 20,000 IU/ml.
In our series, the HBV viral load was not significantly different between AC HDV positive patients and AC HDV negative patients (2.77±1.66 versus
2.65±1.14, p=0.8), Meaning that Delta virus infection did not decrease HBV replication; this finding is consistent with the results found by Mansour W et al [7] in outpatients and those found by Yacoubi L et al [14] (Tunisia) which showed that the viral load of HBV was not significantly different in patients AC HDV Positive versus AC HDV Negative patients (4.08±1.06 vs 4.01±1.59, p=0.79).
On the other hand, the results found by Mansour W et al [5] in DDS showed that the viral load of HBV was significantly higher in DDS AC HDV negative than in DDS AC HDV positive (2.55 ± 1.72 vs. 1.52 ± 1.35, P = 0.001), as well as in pregnant women where the HBV viral load was significantly higher in AC HDV negative pregnant women than in AC HDV positive pregnant women (1.6 ± 1. 6 versus 0.9 ± 0.3, p = 0.001) [7].
In Belgium and France, the viral load of hepatitis B was significantly higher in patients mono-infected with HBV compared to co-infected patients with a significant difference respectively: p=0.02, p=0.001 [28 ,10].
The comparison of the HBV viral load of mono-infected patients to co-infected patients in our series with data from the literature is shown in Table 6.
In Cameroon, patients with a low viral load < 2000> 20,000 IU/ml represented 17.19% and the hepatitis B viral load was significantly higher
(p=0.01) in mono-infected patients (8383192UI/ml or 6.92 log) than in co-infected patients. infected (608813UI/ml or 5.78 log) [22].
The comparison of HBV viral load in mono-infected patients between our series and literature data is shown in Table 7.
Overall, co-infected patients have a lower B viral load than those co-infected with the Delta virus. Indeed, it is classic to note that infection with the hepatitis D virus inhibits the replication of the hepatitis B virus. This inhibition was studied by WU et al [30] who showed that the co-transfection of HBV DNA with HDV cDNA reduced by a factor of 10 the expression of the majority HBV RNAs (3.5 and 2.1 Kb). This action seems to be linked to the small HD protein (195 amino acids). Indeed, the co-transfection of the same cells with HBV DNA and an expression plasmid coding for the small HD protein also decreases the expression of the majority HBV RNAs.
HDV infection does not appear to decrease HBV replication in our study. The fact that a significant proportion of patients mono-infected with HBV were inactive carriers of HBV (62.6% having normal ALT levels and 82.5% having a low viral load below 2000 IU/ml) could be an explanation.
Note that the contagiousness of patients is proportional to their viral loads, whether acute or chronic infection.
4.3. HBe status:
Out of 97 patients among the 211 HBV carriers, 92 HBeAg (-) patients (i.e. 94.9% of patients) and 5 HBeAg (+) patients (i.e. 5.1%) were found. This is close to the results of Lunel - Fabiani F [19] who showed that 7.2% of patients were HBeAg (+) and 92.8% of patients were HBeAg (-).
In Cameroon 14/128 (i.e. 10.94%) of patients have HBeAg (+), and 114/128 (i.e. 89.06%) have HBeAg (-) [22].
In Tunisia nearly 95% of patients were AgHBe (-) [14].
In our series, HBe status is strongly correlated with HBV viral load (p=0.00). All HBeAg positive patients (5 patients) had a viral load ≥ 2000 IU/ml, of which 2 patients had an intermediate viral load between 2000 and 20,000 IU/ml and 3 patients had a high viral load greater than 20,000 IU/ml. In fact, HBeAg, alongside DNA, is a marker of viral replication.
Among the 92 HBeAg (-) patients, 7 patients (i.e. 7.6%) have an intermediate viral load between 2000 and 20,000 IU/ml, and 7 patients (i.e. 7.6%) have a high viral load greater than 20,000 IU/ml which could be explained by the circulation of mutant strains (pre-core mutants) in our country.
In Cameroon, all HBe Ag (+) patients had HBV DNA levels above 20,000 IU/ml while 7 patients (i.e. 6.14%) had HBV DNA levels above 20,000 IU/ml in Cameroon. HBe Ag (-) patients [22].
In our series, we noticed that co-infection has no influence on HBe status (p=0.22), which is consistent with the study by Torimiro JN et al [22] in Cameroon (p= 0.43).
4.4. Other biological parameters:
These parameters are very little studied in the literature that we consulted.
In our series, the ALT level was not significantly different between AC HDV positive patients and AC HDV negative patients (p = 0.27). was found in 13.04% of mono-infected patients and 17.39% of co-infected patients, which is comparable to the results of Yacoubi L et al [14] (Tunisia) which showed that the ALT level did not was not significantly different from AC HDV positive patients compared to AC HDV negative patients (p = 0.5) and also comparable to the results of Keshvari M et al [9] (Iran) which showed that the ALT level was not not significantly different from AC HDV positive patients compared to AC HDV negative patients (p=0.3).
On the other hand, in the study by Lunel-Fabiani F et al [19], AC HDV positive patients had higher ALT levels with a significant difference (p<0>
In Belgium, the ALT level more than twice the normal is found in 13.66% of patients mono-infected with HBV, 34.48% of co-infected patients and co-infected patients had values of ALAT significantly higher (p=0.002) [28].
In our series, the ALT level was significantly higher in patients with a high viral load (p=0.00), as was the AFP level (p=0.01).
This marker of cytolysis seems to be increased by Delta co-infection according to most authors, contrary to what we observed in this study.
In our series, there is no significant difference in AFP (p=0.3) in co-infected patients compared to mono-infected patients.
This prospective study carried out on 211 patients carrying HBsAg aimed to study the prevalence of HBV and HDV co-infection, the influence of co-infection on the B viral load, the relationship between HBe seroconversion and the viral HBV and the influence of HBV/HDV co-infection on HBe seroconversion, as well as the study of other biological parameters (ALAT, PT, platelets, bilirubin, AFP).
Regarding HBsAg carriage, our study shows a male predominance with a sex ratio of 1.45. It confirms the high prevalence of HBV/HDV co-infection in our country (31.3%).
The average age of our patients was 36 years old and the most affected age group is 40-49 years old (27.90%) followed by 20-29 years old (24.41%) with no significant difference between the 2 sexes.
The average HBV viral load in our series was 2.68 ± 1.31 log IU/ml (i.e. 478.63 IU/ml ± 20.41), 10.4% of our patients had an intermediate viral load between 2000 and 20,000 IU/ml and 7.1% of the patients had a high viral load above 20,000 IU/ml and there is no significant difference between the viral load of AC HDV positive patients and AC HDV negative patients.
In our series, HBe status is strongly correlated with HBV viral load and all HBe Ag (+) patients had a viral load greater than 2000 IU/ml. However, no relationship has been established between HBe status and HBV/HDV co-infection.
ALT and AFP levels were not significantly not different from co-infected patients compared to mono-infected patients.
HBV/HDV superinfection is associated with rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma, which prompted us to make this
Study which is very limited by the number of staff and the absence of imaging or pathology data that could demonstrate complications of hepatitis B virus infection or HBV / HDV coinfection, the burden viral Delta could not also be carried out, it shows a high prevalence of co-infection by the delta virus in carriers of the hepatitis B virus, which is alarming in our context where the prevalence of hepatitis B is very high.
Conflict of interest: none
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
